<DOC>
	<DOC>NCT02294396</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with overactive bladder (OAB) on mirabegron.</brief_summary>
	<brief_title>Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.</brief_title>
	<detailed_description>This is a multicenter, open label study to evaluate the safety and efficacy of add-on therapy with anticholinergics in OAB patients on mirabegron. The duration of the study period will be 54 weeks in total, comprising a 2-week screening period and a 52-week treatment period.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Propiverine</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Female: OAB outpatient who has been postmenopausal for at least 1 year Male: OAB outpatient who has no wish to have children in the future Patient has been under treatment with mirabegron at a stable dose of 50 mg once daily for at least 6 weeks before the start of the screening period Patient can walk to the bathroom without assistance Patient has a total Overactive Bladder Symptom Score (OABSS) of ≥3 points and a Question 3 score of ≥2 points Patient has an established diagnosis of stress urinary incontinence (patient has no symptom other than stress urinary incontinence) Patient has urinary tract infection (cystitis, prostatitis, etc.), urinary calculus (ureteric calculus, urethral calculus, bladder calculus, etc.), interstitial cystitis, or a history of recurrent urinary tract infection (at least 3 episodes within 24 weeks before the start of the screening period) Patient has a residual urine volume of ≥100 mL at week 2 visit or patient with benign prostatic hyperplasia or lower urinary tract obstruction Patient has uncontrolled hypertension (sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at week 2 visit) Patient has a pulse rate of ≥110 bpm or &lt;50 bpm at week 2 visit Anticholinergics are contraindicated (urinary retention; obstruction in the pylorus, duodenum, or intestine; paralytic ileus; gastric/intestinal atony; myasthenia gravis; and decreased gastrointestinal motility/tone, etc.) for the patient. Patient has glaucoma, ulcerative colitis, hyperthyroidism, dementia, cognitive dysfunction, parkinsonism symptoms, or clinically significant cerebrovascular disorder Patient has serious heart disease (myocardial infarction, cardiac failure, uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver disease, kidney disease, immunological disease, lung disease, etc. or patient has or has a history of malignant tumor (except for malignant tumor that has not been treated for at least 5 years before the start of the screening period with no risk of recurrence) Patient has drug hypersensitivity to βagonists or anticholinergics Patient is under treatment with flecainide acetate or propafenone hydrochloride Patient has long QT syndrome, patient is vulnerable to arrhythmia such as bradycardia or acute myocardial ischemia, patient has hypokalemia, and patient has ischemic heart disease such as angina pectoris Patient has used any prohibited concomitant medication within 4 weeks before the start of the screening period Patient is under catheterization or intermittent selfcatheterization or patient has pelvic organ prolapse that affects the urinary tract function Patient has received radiotherapy that affects the urinary tract function Patient has received surgical therapy that may affect the urinary tract function within 24 weeks before the start of the screening period Patient has received nonpharmacological therapy for OAB such as electric stimulation therapy (interferential low frequency therapy, magnetic stimulation therapy, etc.), biofeedback therapy, bladder training, or pelvic floor muscle exercise within 2 weeks before the start of the screening period Patient has or has a history of mood disorder, neurotic disorder, and schizophrenia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Anticholinergic</keyword>
	<keyword>Overactive Bladder (OAB)</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>YM178</keyword>
</DOC>